Zabadinostat (formerly CXD101) is a small molecule epigenetic regulator. It controls genes involved in antigen presentation (AP) and natural killer (NK) cell activity. Zabadinostat has undergone extensive scientific and clinical studies which suggest a highly competitive safety and efficacy profile. Clinically, it is being trialed in microsatellite-stable (MSS) colorectal cancer, hepatocellular carcinoma (HCC; the most common form of liver cancer), and refractory / relapsed peripheral T-cell lymphoma (PTCL).
CAROSELL Study on Colorectal Cancer
This study was focused on gathering clinical data to provide regulatory bodies.We recently completed a Phase II study of 55 patients in MSS CRC patients (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808483/).
HACCA Study on Liver Cancer
This clinical study is focused on gathering data to determine the efficacy of zabadinostat in combination with animmune checkpoint inhibitor (“ICI”) in resistant hepatocellular carcinoma (“HCC”).
PARTICL Study on Lymphoma
This clinical study is focused on gathering data to determine the efficacy of zabadinostat as a monotherapy in refractory or relapsed peripheral T-cell lymphoma (“PTCL”). A previous Phase I study of zabadinostat showed clinical activity in PTCL and follicular lymphoma.